Skip to main content
SpringerLink
Log in

Pharmacology of Bromocriptine in Health and Disease

  • Evaluations on New Drug
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Bromocriptine1, a lysergic acid derivative with a bromine atom at position 2, has been found to have unique effects on the dopamine receptors in the pituitary and central nervous system and peripherally. It is rapidly and completely absorbed from the gut and is mainly excreted in the bile and faeces. It seems to have a particular specificity for the pituitary prolactinotrophe although it does have other effects in different disease states. In spite of the fact that it is an ergot derivative, it is remarkably free of ergot vascular side effects in the doses needed for therapeutic benefit. The most common adverse effects are nausea, vomiting and postural symptoms. These can be overcome by starting at low doses and increasing to therapeutic levels. Its major use is in the suppression of prolactin in states where this hormone is elevated irrespective of cause. It has also been used in the treatment of acromegaly and is under investigation for use in other disease states probably linked with the prolactin system or dopaminergic receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bassi, F.; Giusti, G.; Borsi, L.; Cattaneo, S.; Giannotti, P.; Forti, G.; Pazzagli, M.; Vigiani, C. and Serio, M.: Plasma androgens in women with hyperprolactinemic amenorrhoea. Clinical Endocrinology 6: 5 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Benedek-Jaszmann, L.J. and Hearn-Sturtevant, M.D.: Premenstrual tension and functional infertility: Aetiology and treatment. Lancet 1: 1095 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Besser, G.M.: Absence of uterine neoplasia in patients on bromocriptine. British Medical Journal 2: 868 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Besser, G.M.: Bromocriptine and the tubero-infundibular system: Hyperprolactinemia. Triangle 17: 33 (1978)

    Google Scholar 

  • Besser, G.M. and Wass, J.A.H.: Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years. Medical Journal of Australia 2 (Suppl.): 31 (1978)

    PubMed  CAS  Google Scholar 

  • Besser. G.M.; Parke, L.; Edwards, C.R.W.; Forsyth, I.A. and McNeilly, A.S.: Galactorrhea: successful treatment with reduction of plasma prolactin levels by bromoergocryptine. British Medical Journal 3: 669 (1972)

    Article  PubMed  CAS  Google Scholar 

  • Billeter. E. and Fluckiger, E.: Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-α-ergocryptine. Experientia 27: 464 (1971)

    Article  PubMed  CAS  Google Scholar 

  • Caldara, R.; Grimoldi, D. and Ferrari, C.: Bromocriptine, gastric acid output and gastrin secretion. Lancet 1: 902 (1977)

    Article  Google Scholar 

  • Calne, D.B.; Claveria, L.E. and Reid, J.L.: Hypothermic action of bromocriptine. British Journal of Pharmacology 54: 123 (1975)

    PubMed  CAS  Google Scholar 

  • Camanni. F.; Massara, F.; Belforte, L. and Molinatti, G.M.: Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-Br-α-ergocryptine. Journal of Clinical Endocrinology and Metabolism 40: 363 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Caron, M.G.; Drouin, J. and Raymond, V.: Specificity of the catecholaminergic effect on prolactin secretion and (3H)-dihydroergocryptine binding. Clinical Research 24: 656A (1976)

    Google Scholar 

  • Carter, J.N.; Tyson, J.E.; Tolis, G.; Van Vliet, S.; Faiman, C. and Friesen, H.G.: Prolactin secreting tumors and hypogonadism in 22 men. New England Journal of Medicine 299: 847 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Clark, B.J.: Dopamine receptor stimulants in hypertension. Acta Medica Scandinavica Suppl. 606: 95 (1977)

    CAS  Google Scholar 

  • Cole, E.N.; Sellwood, R.A. and England, P.C.: Serum prolactin concentrations in benign breast disease throughout the menstrual cycle. European Journal of Cancer 13: 597 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Corrodi, H.; Fuxe, K.; Hokfelt, T.; Lidbrink, P. and Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. Journal of Pharmacy and Pharmacology 25: 409 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Cowan. G.O.: Bromocriptine and gastric acid output. Lancet 1: 425 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Davies, C.; Jacob, J.; Lloyd, H.M. and Meares, J.D.: DNA synthesis and the secretion of prolactin and growth hormone by the pituitary gland of the male rat: effect of diethylstilboestrol and 2-Br-α-ergocryptine. Journal of Endocrinology 61: 411 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Del Pozo, E.: Clinical use of bromocriptine. Endocrine Society of Australia. 19th Annual Meeting, Brisbane 19: 57 (August 1976)

    Google Scholar 

  • Del Pozo, E. and Fluckiger, E.: Pharmacological aspects of the prolactin inhibitor bromocriptine; in Tolis, Labrie, Martin and Naftolin (Eds) Clinical Neuroendocrinology. A Pathophysiological Approach (Raven Press, in press 1979)

  • Del Pozo, E. and Ohnhaus, E.E.: Lack of effect of acute prolactin suppression on renal water, sodium and potassium excretion during sleep. Hormone Research 7: 11 (1976)

    Article  PubMed  Google Scholar 

  • Del Pozo, E.; Brun del Re; Varga, L. and Friesen, H.: Inhibition of prolactin secretion in man by CB 1 54 (2-Br-α-ergocriptine). Journal of Clinical Endocrinology and Metabolism 35: 768 (1972)

    Article  PubMed  Google Scholar 

  • DelPozo, E.; Brun del Re; de Grandi, P.; Friesen, H.; Hinselmann, M. and Wyss, H.: Prolactin inhibition and suppression of puerperal lactation by Br-ergocriptine (CB 154). A comparison with estrogen. Obstetrics and Gynecology 41: 884 (1973) a

    PubMed  Google Scholar 

  • DelPozo, E.; Friesen, H. and Burmeister, P.: Endocrine profile of a specific prolactin inhibitor: Br-ergokryptine. A preliminary report. Schweizerische Medizinische Wochenschrift 103: 847 (1973) b

    PubMed  Google Scholar 

  • DelPozo, E.; Darragh, A.; Lancranjan, I.; Ebeling, D.; Burmeister, P.; Buhler, F.; Marbach, P. and Braun, P.: Effect of bromocriptine on the endocrine system and fetal development. Clinical Endocrinology 6(Suppl.): 47s (1977)

    Article  PubMed  Google Scholar 

  • DelPozo, E.; Schulz, K.D.; Wyss, H.; Lancranjan, I. and Braun, P.: Effect of prolactin on mechanisms of ovulation and on pregnancy: some recent fidings; in Robyn and Harter (Eds) Progress in Prolactin Physiology and Pathology, p.281 (Biomedical Press, North Holland 1978)

    Google Scholar 

  • Eddy, R.L.; Jones, A.L.; Chakmakjian, Z.H. and Silverthorne, M.C.: Effect of L-dopa on human hypophyseal trophic hormone release. Journal of Clinical Endocrinology and Metabolism 33: 709 (1971)

    Article  PubMed  CAS  Google Scholar 

  • Edwards, C.R.W.; Miall, P.A.; Hamker, J.P.; Thorner, M.O.; Al-Dujaili, E.A.S. and Besser, G.M.: Inhibition of the plasma aldosterone response to frusemide by bromocriptine. Lancet 2: 903 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Erero, M.A. and Langer, S.Z.: Inhibition by dopamine of 3H-noradrenaline release elicited by nerve stimulation in the isolated cat’s nictitating membrane. Naunyn-Schmiedebergs Archives of Pharmacology 289: 179 (1975)

    Article  Google Scholar 

  • Fluckiger, E.: Pharmacological characterization of CB 154. Triangle 14: 153 (1975)

    Google Scholar 

  • Fluckiger, E.: The pharmacology of bromoergocryptine: in Bayliss, Turner and Maclay (Eds) Pharmacological and Clinical Aspects of Bromoergocryptine (Parlodel), p.12 (Tunnbridge Wells, London 1976)

    Google Scholar 

  • Fluckiger, E.; Doepener, W.; Marko, M. and Niederer, W.: Effects of ergot alkaloids on the hypothalamic pituitary axis. Postgraduate Medical Journal 52 (Suppl. 1): 57 (1976)

    Google Scholar 

  • Franks, S.; Jacobs, H.S.; Hull, M.G.; Steele, S.J. and Nabarro, J.D.N.: Management of hyperprolactinemic amenorrhea. British Journal of Obstetrics and Gynaecology 84: 241 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Friesen, H. and Tolis, G.: Use of bromocriptine in the galactorrhoea-amenorrhoea syndromes. The Canadian Cooperative Study. Clinical Endocrinology 6 (Suppl.): 91s (1977)

    Article  PubMed  Google Scholar 

  • Friesen, H.; Shiu, R. and Hwang, P.: Studies on human prolactin. Chemistry, radioreceptor assay and clinical significance; in Pasteels and Robyn (Eds) Human Prolactin. Proceedings of the International Symposium on Human Prolactin, Brussels, p.11 (Excerpta Medica, Amsterdam 1973)

    Google Scholar 

  • Fuxe, K.; Hokfelt, T.; Jonsson, G. and Lobstrom, A.: In Vollrath and Knowles (Eds) Neurosecretion — The Final Neuroendocrine Pathway, p.269 (Springer-Verlag, Berlin 1973)

    Google Scholar 

  • Fuxe. K.; Agnati, L.F. and Corrodi, H.: Action of dopamine receptor agonists in forebrain and hypothalamus; rotational behaviour, ovulation and dopamine turnover; in Calne, Chase and Barbeau (Eds) Advances in Neurology, Vol. 9, p.223 (Raven Press, New York 1975)

    Google Scholar 

  • Gautvik, K.M.; Hoyt, R.F. and Tashjian, A.H.: Effects of colchicine and 2-Br-α-ergokryptine methanesulphonate on the release of prolactin and growth hormone by functional pituitary tumour cells in culture. Journal of Cellular Physiology 82: 401 (1973)

    Article  PubMed  CAS  Google Scholar 

  • Ghose, K. and Coppen, A.: Bromocriptine and premenstrual syndrome: a controlled study. British Medical Journal 1: 147 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Graf, K.J.; Neumann, F. and Horowski, R.: Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98: 598 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Grauwiler, J. and Griffith, R.W.: Acute toxicity studies with 2-Br-alpha-ergocryptine mesylate. IRCS Medicine and Science Library Compendium 2: 1516 (1974)

    CAS  Google Scholar 

  • Griffith, R.W.: Toxicity studies with 2-Br-alpha-ergocriptine mesylate: effect of prolonged oral administration in rats. IRCS Medicine and Science Library Compendium 2: 1661 (1974)

    CAS  Google Scholar 

  • Griffith, R.W.; Trukalj, I. and Braun, P.: Outcome of pregnancy in mothers given bromocriptine. British Journal of Clinical Pharmacology 5: 227 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Hamilton, J.M.; Flaks, A.; Saluja, P.G. and Maguire, S.: Hormonally induced renal neoplasia in the male Syrian hamster and the inhibitory effect of 2-Br-α-ergocriptine methanesulfonate. Journal of the National Cancer Institute 54: 1385 (1975)

    PubMed  CAS  Google Scholar 

  • Hayek, A. and Crawford, J.D.: L-dopa and pituitary hormone secretion. Journal of Clinical Endocrinology and Metabolism 34: 764 (1972)

    Article  PubMed  CAS  Google Scholar 

  • Heuson, J.C.; Coune, A. and Staquet, M.: Clinical trial of 2-Br-alpha-ergocryptine (CB154) in advanced breast cancer. European Journal of Cancer 8: 155 (1972)

    Article  Google Scholar 

  • Hirst, B.H.; Lund, P.K.; Reed, J.D. and Sanders, D.J.: Bromocriptine, gastric acid output and gastrin secretion. Lancet 1: 902 (1977)

    Google Scholar 

  • Hokfelt, T. and Fuxe, K.: On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons; in Krigge, Scott and Weindel (Eds) Brain Endocrine Interactions, p.181 (S. Karger, Basel 1972) a

    Google Scholar 

  • Hokfelt, T. and Fuxe, K.: Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine neurons. Neuroendocrinology 9: 100 (1972)b

    Article  PubMed  CAS  Google Scholar 

  • Horrobin, D.F.; Mahajan, K.K. and Robinson, C.J.: Metabolic effects of bromoergokryptine in the rat. Journal of Endocrinology 64: 587 (1975)

    Article  PubMed  Google Scholar 

  • Ishibashi, M. and Yamaji, T.: Effect of TRH and bromoergocriptine on GH and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Journal of Clinical Endocrinology and Metabolism 47: 1251 (1978)

    Article  PubMed  CAS  Google Scholar 

  • Judd, S.; Lazarus, L. and Smythe, G.: Bromo-ergocryptine-medieval medicine revisited. Bulletin of the Postgraduate Committee in Medicine, University of Sydney (April 1977)

  • Kimura, H.; Calabro, M.A. and MacLeod, R.M.: Suppression of prolactin secretion and cAMP accumulation by dopamine in the pituitary. Federation Proceedings 35: 305 (1976)

    Google Scholar 

  • Kobberling, J.; Juppner, H.; Volkmann, B.; Unger, K.; Schwinn, G. and Dirks, H.: Suppression of growth hormone by bromocriptine in acromegalics, lack of suppression in normals. Acta Endocrinologica 78 (Suppl. 193): 93 (1975)

    Google Scholar 

  • Lachelin, G.C.L.; Leblanc, H. and Yen, S.S.C.: Inhibitory effect of dopamine agonists on LH release in women. Journal of Clinical Endocrinology and Metabolism 44: 728 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Lamberts, S.W.J. and Birkenhager, J.C.: Effect of bromocriptine in pituitary dependent Cushing’s syndrome. Journal of Endocrinology 70: 315 (1976)a

    Article  PubMed  CAS  Google Scholar 

  • Lamberts, S.W.J. and Birkenhager, J.C.: Bromocriptine in Nelson’s syndrome and Cushing’s disease. Lancet 2: 811 (1976)b

    Article  PubMed  CAS  Google Scholar 

  • Langer, S.Z.: Presynaptic regulation of norepinephrine release elicited by nerve stimulation. Life Sciences 13: 97 (1973)

    Article  Google Scholar 

  • Lees, A.J.: Bromocriptine. British Journal of Hospital Medicine 18: 336 (1977)

    PubMed  CAS  Google Scholar 

  • Liuzzi, A.; Panerai, A.E.; Chiodini, P.G.; Secchi, C.; Cocchi, D.; Botalla, L.; Silvestrini, F. and Muller, E.E.: In Pecile and Muller (Eds) Growth Hormone and Related Peptides, p.236 (Excerpta Medica, Amsterdam 1976)

    Google Scholar 

  • Lloyd, H.M.; Meares, J.D. and Jacobi, J.: Effects of estrogen and bromocriptine on the in vivo secretion and mitosis in prolactin cells. Nature 255: 497 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Lutterbeck, P.M.; Pryor, J.S.; Varga, L. and Wenner, R.: Treatment of non-puerperal galactorrhea with an ergot alkaloid. British Medical Journal 3: 228 (1971)

    Article  PubMed  CAS  Google Scholar 

  • McCulloch, M.W.; Rand, M.J. and Story, D.F.: Evidence for a dopaminergic mechanism for modulation of adrenergic transmission in the rabbit ear artery. British Journal of Pharmacology 49: 141P (1973)

    Article  Google Scholar 

  • MacLeod, R.M.: Regulation of prolactin secretion; in Martini and Ganong (Eds) Frontiers in Neuroendocrinology, Vol. 4, p. 169 (Raven Press, New York 1976)

    Google Scholar 

  • MacLeod, R.M. and Krieger, D.T.: Differential effect of ergotamine on ACTH and prolactin secretion. 58th Annual Meeting of the Endocrine Society. Abstract 317 (1976)

  • MacLeod, R.M. and Lehmeyer, J.E.: Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94: 1077 (1974)

    Article  PubMed  CAS  Google Scholar 

  • McNatty, K.P.; Sawers, R.S. and McNeilly, A.S.: A possible role for prolactin in the control of steroid secretion by the human Graafian follicle. Nature 250: 653 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Mahajan, K.K.; Manku, M.S.; Davidson, H.; James, M.F.; Robinson, C.J. and Horrobin, D.F.: Renal interactions of prolactin and bromocriptine. Journal of Endocrinology 68: 14P (1976)

    Google Scholar 

  • Maneschi, F.; Cionini, R.; Rolla, M. and Navalesi, R.: Shock syndrome after bromocriptine. Lancet 2: 462 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Marko, M. and Fluckiger, E.: Inhibition of spontaneous and induced ovulation in rats by non-steroidal agents. Acta Endocrinologica 73 (Suppl. 177): 139 (1973)

    Google Scholar 

  • Martin-Comin, J.; Pujol-Amat, P.; Cararachi, V.; Davi, E. and Robyn, C.: Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-α-ergocryptine. Obstetrics and Gynecology 48: 703 (1976)

    PubMed  CAS  Google Scholar 

  • Meyer, M.B.; McNay, J.L. and Goldberg, L.I.: Effects of dopamine on renal function and hemodynamics in the dog. Journal of Pharmacology and Experimental Therapeutics 156: 186 (1967)

    PubMed  CAS  Google Scholar 

  • Miller, R.J. and Iversen, L.L.: Stimulation of a dopamine sensitive adenylate cyclase in homogenates of rat striatum by a metabolite of a piribedil. Naunyn-Schmiedebergs Archives of Pharmacology 282: 213 (1974)

    Article  CAS  Google Scholar 

  • Minozzi, M.; Faggiano, M.; Lombardi, G.; Carella, G.; Criscuolo, T. and Scapagnini, U.: Effect of L-dopa on plasma TSH levels in primary hypothyroidism. Neuroendocrinology 17: 147 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Miyai, K.; Onishi, T.; Hosokawa, M.; Ishibashi, K. and Kumahara, Y.: Inhibition of thyrotropin and prolactin secretion in primary hypothyroidism by 2-Br-α-ergocryptine. Journal of Clinical Endocrinology and Metabolism 39: 39 (1974)

    Article  Google Scholar 

  • Morgan, M.Y.; Jakobovits, A.; Elithorn, A.; James, I.M. and Sherlock, S.: Successful use of bromocriptine in the treatment of a patient with chronic portasystemic encephalopathy. New England Journal of Medicine 296: 793 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Muller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn Schmiedebergs Archives of Pharmacology 292: 113 (1976)

    Article  CAS  Google Scholar 

  • Muller-Schweinitzer, E. and Sturmer, E.: Investigations of the mode of action of ergotamine in the isolated femoral vein of the dog. British Journal of Pharmacology 51: 441 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Muller, E.E.; Gil-ad, I.; Panerai, A.E.; Secchi, C.; Liuzzi, A.; Chiodini, P.G. and Silvestrini, F.: In Charro-Salgado, Fernandez-Durango and Del Campo (Eds) Basic Applications and Clinical Uses of Hypothalamic Hormones, p.211 (Excerpta Medica, Amsterdam 1976)

    Google Scholar 

  • Muller, E.E.; Panerai, A.E.; Cocchi, D. and Mantegazza, P.: Endocrine profile of ergot alkaloids. Life Sciences 21: 1545 (1977) a

    Article  PubMed  CAS  Google Scholar 

  • Muller, E.E.; Liuzzi, A.; Cocchi, D.; Panerai, A.E.; Oppizzi, G.; Locatelli, V.; Mantegazza, P.; Silvestrini, F. and Chiodini, P.G.: In Costa and Gessa (Eds) Advances in Biochemical Psychopharmacology, Vol. 16, p. 127 (Raven Press, New York 1977) b

    Google Scholar 

  • Nagasawa, H.; Yanai, R. and Fluckiger, E.: Counteraction of 2-Br-α-ergocriptine of pituitary prolactin release promoted by dibutyryl adenosine 3′5′-monophosphate, in rats; in Pasteels and Robyns (Eds) Human Prolactin p.313 (Excerpta Medica, Amsterdam 1973)

    Google Scholar 

  • Niswender, G.D.: Effect of ergocornine on reproduction in sheep. Biology of Reproduction 7: 138 (1972)

    Google Scholar 

  • Parkes, D.: Bromocriptine. Advances in Drug Research 12: 247 (1978)

    Google Scholar 

  • Parkes, J.D.; Marsden, C.D.; Donaldson, I.; Galea-Debono, A.; Walters, J.; Kennedy, G. and Asselman, P.: Bromocriptine treatment in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 39: 184 (1976)

    Article  CAS  Google Scholar 

  • Pasteels, J.L.; Danguy, A.; Frerotte, M. and Ectors, F.: Inhibition de la secretion de prolactine par rergocornine et la 2-Br-α-ergokryptine: Action directe sur l’hypophyse en culture. Annales D’Endocrinologie 32: 188 (1971)

    PubMed  CAS  Google Scholar 

  • Penny, R.J. and Thody, A.J.: Preliminary studies on the control of α-melanocyte stimulating hormone secretion in the rat. Journal of Endocrinology 69: 2P (1976)

    Google Scholar 

  • Quadri, S.K. and Meites, J.: Effects of ergocornine and CG 603 on blood prolactin and GH in rats bearing a pituitary tumor (37128). Proceedings of the Society for Experimental Biology and Medicine 142: 837(1973)

    PubMed  CAS  Google Scholar 

  • Rand, M.J.; Story, D.F. and McCulloch, M.W.: Inhibitory feedback modulation of adrenergic transmission. Clinical Experimental Pharmacology and Physiology Suppl. 2: 21 (1975)

    CAS  Google Scholar 

  • Reubi, J.C.; Iversen, L.L. and Jessel, T.M.: Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra in vitro. Nature 268: 652 (1977)

    Article  PubMed  CAS  Google Scholar 

  • Sachdev, Y.; Tunbridge, W.M.G.; Weightmann, R.D.; Gomez-Pan, A.; Duns, A. and Hall, R.: Bromocriptine therapy in acromegaly. Lancet 2: 1164 (1975)

    Article  PubMed  CAS  Google Scholar 

  • Salih, H.; Flax, H.; Brander, W. and Hobbs, J.A.: Prolactin dependence in human breast cancers. Lancet 2: 1103 (1972)

    Article  PubMed  CAS  Google Scholar 

  • Schams, D.: Prolactin releasing effects of TRH in the bovine and their depression by a prolactin inhibitor. Hormone and Metabolic Research 4: 405 (1972)

    Article  PubMed  CAS  Google Scholar 

  • Schams, D.; Reinhardt, V. and Karg, H.: Effects of 2-Bromoergocriptine on plasma prolactin level during parturition and onset of lactation in cows. Experientia (Basel) 28: 697 (1972)

    Article  CAS  Google Scholar 

  • Scholtysik, G. and Birde, B.: Dopamine receptor mediated inhibition by bromocriptine of accelerator nerve stimulation effects in the pithed cat. British Journal of Pharmacology 62: 379P (1978)

    Google Scholar 

  • Schulz, K.D.; Geiger, W.; Del Pozo, E.; Kunzig, H.G.; Lancrantan, I. and Lose, K.H.: Influence of the prolactin inhibitor bromocriptine on human luteal function in vivo. Archive Gynakologie 221: 93 (1976)

    Article  CAS  Google Scholar 

  • Seki, M.; Seki, K.; Yoshihara, T.; Watanabe, N.; Okumura, T.; Tajima, C.; Huang, S.Y. and Kuo, C.C.: Direct inhibition of pituitary LH secretion in rats by CB 154. Endocrinology 94: 911 (1974)

    Article  PubMed  CAS  Google Scholar 

  • Seppala, M., Hirvonen, E. and Ranta, T.: Hyperprolactinemia and luteal insufficiency. Lancet 1: 229 (1976)

    PubMed  Google Scholar 

  • Shipley, R.E. and Tilden, J.H.: A pithed rat preparation suitable for assaying pressor substances. Proceedings of the Society for Experimental Biology and Medicine 64: 453 (1947)

    PubMed  CAS  Google Scholar 

  • Strumer, E. and Fluckiger, E.: In vivo smooth muscle stimulant activity of 2-Br-α-ergocryptine as compared with that of ergotamine. IRCS Medicine and Science Library Compendium 2: 1591 (1974)

    Google Scholar 

  • Tashjian, A.H. and Hoyt, R.F.: Transient control of organ specific functions in pituitary cells in culture: in Sussman (Ed) Molecular Genetics and Developmental Biology, p.353 (Prentice Hall, New Jersey 1972)

    Google Scholar 

  • Tolis, G. and Friesen, H.G.: The control of prolactin secretion. International Congress on Hypothalamic Hormones, Calgary 1973, p.91 (Karger, Basel 1974)

    Google Scholar 

  • Tolis, G. and Friesen, H.: Prolactin and human reproduction. Canadian Medical Association Journal 115: 709 (1976)

    PubMed  CAS  Google Scholar 

  • Tolis, G. and Naftolin, F.: Induction of menstruation with bromocriptine in patients with euprolactinemic amenorrhea. American Journal of Obstetrics and Gynecology 126: 406 (1976)

    Google Scholar 

  • Tolis, G. and Van Vliet, S.: Leydig cell function in hyperprolactinemia. Clinical Research 24(3): 279A (1976)

    Google Scholar 

  • Tolis, G.; Pinter, E.J. and Friesen, H.: Acute effects of 2-Bromo-α-ergocriptine (CB154) on anterior pituitary hormones and free fatty acids in man. International Journal of Clinical Pharmacology and Biopharmacy 12: 281 (1975)

    PubMed  CAS  Google Scholar 

  • Trabucchi, M.; Spano, P.F.; Tonon, G.L. and Frattola, L.: Effects of bromocriptine on central dopaminergic receptors. Life Sciences 19: 225 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Wass, J.A.H.; Thorner, M.O. and Besser, G.M.: Gastrointestinal bleeding in patients on bromocriptine. Lancet 2: 851 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Yeh, B.K.; McNay, J.L. and Goldberg, L.I.: Attenuation of dopamine renal and mesenteric vasodilation by haloperidol. Evidence for a specific receptor. Journal of Pharmacology and Experimental Therapeutics 168: 303 (1969)

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, H3A 1A1, Canada

    A. E. Mehta &  G. Tolis

Authors
  1. A. E. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Tolis
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

‘Parlodel’, ‘Pravidel’ (Sandoz).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, A.E., Tolis, G. Pharmacology of Bromocriptine in Health and Disease. Drugs 17, 313–325 (1979). https://doi.org/10.2165/00003495-197917050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-197917050-00001

Keywords

Search

Navigation